These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29468454)

  • 21. A double blind comparative study of tegafur (FT) and UFT (a combination of Tegafur and uracil) in advanced breast cancer.
    Tashiro H; Nomura Y; Ohsaki A
    Jpn J Clin Oncol; 1994 Aug; 24(4):212-7. PubMed ID: 8072200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer--a single institute study.
    Nio Y; Koike M; Omori H; Hashimoto K; Itakura M; Yano S; Higami T; Maruyama R
    Anticancer Res; 2004; 24(3b):1879-87. PubMed ID: 15274369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uracil/tegafur plus oral calcium folinate in advanced breast cancer.
    Richardet E; Pedraza C; Mickiewicz E; Lerzo G; Bonamasa M; Coppola F; Elli A; Uranga G; Jovtis S; Bruno M; Ventriglia M; Cuevas MA; Alvarez AM; Suarez LA; Fein L
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):96-7. PubMed ID: 10442373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer.
    Ichikura T; Tomimatsu S; Okusa Y; Yahara T; Uefuji K; Tamakuma S
    Cancer Chemother Pharmacol; 1996; 38(5):401-5. PubMed ID: 8765432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
    J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
    Toi M; Ikeda T; Akiyama F; Kurosumi M; Tsuda H; Sakamoto G; Abe O
    Int J Oncol; 2007 Oct; 31(4):899-906. PubMed ID: 17786323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
    Meropol NJ; Sonnichsen DS; Birkhofer MJ; Ferreira I; Noel D
    Cancer Chemother Pharmacol; 1999; 43(3):221-6. PubMed ID: 9923552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis of five studies on tegafur plus uracil (UFT) as post-operative adjuvant chemotherapy for breast cancer.
    Kasumi F; Yoshimoto M; Uchino J; Abe R; Nomura Y; Sugimachi K; Nakazato H; Abe O
    Oncology; 2003; 64(2):146-53. PubMed ID: 12566912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
    Pazdur R; Lassere Y; Diaz-Canton E; Ho DH
    Cancer Invest; 1998; 16(3):145-51. PubMed ID: 9541627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
    Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
    Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer.
    Watanabe T
    Breast Cancer; 2013 Oct; 20(4):302-9. PubMed ID: 23456736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
    Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
    J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
    Okabayashi K; Hasegawa H; Ishii Y; Endo T; Ochiai H; Kubota T; Kitagawa Y
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):501-7. PubMed ID: 18461329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
    Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
    Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
    Hasegawa K; Saiura A; Takayama T; Miyagawa S; Yamamoto J; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Oba M; Takahashi M; Mizunuma N; Matsuyama Y; Watanabe T; Makuuchi M; Kokudo N
    PLoS One; 2016; 11(9):e0162400. PubMed ID: 27588959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis.
    Nakagawa R; Inoue Y; Ohki T; Kaneko Y; Maeda F; Yamamoto M
    World J Surg Oncol; 2017 May; 15(1):112. PubMed ID: 28566093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
    Polychronis A; Sinnett HD; Hadjiminas D; Singhal H; Mansi JL; Shivapatham D; Shousha S; Jiang J; Peston D; Barrett N; Vigushin D; Morrison K; Beresford E; Ali S; Slade MJ; Coombes RC
    Lancet Oncol; 2005 Jun; 6(6):383-91. PubMed ID: 15925816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.